These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 1503679

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.
    Dettling M, Sachse C, Müller-Oerlinghausen B, Roots I, Brockmöller J, Rolfs A, Cascorbi I.
    Pharmacopsychiatry; 2000 Nov; 33(6):218-20. PubMed ID: 11147929
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.
    Honigfeld G.
    Psychiatr Serv; 1996 Jan; 47(1):52-6. PubMed ID: 8925346
    [Abstract] [Full Text] [Related]

  • 48. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience.
    Alvir JM, Lieberman JA.
    J Clin Psychopharmacol; 1994 Apr; 14(2):87-9. PubMed ID: 8195462
    [No Abstract] [Full Text] [Related]

  • 49. Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.
    Islam F, Hain D, Lewis D, Law R, Brown LC, Tanner JA, Müller DJ.
    Pharmacogenomics J; 2022 Jul; 22(4):230-240. PubMed ID: 35710824
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Clozapine-induced agranulocytosis: Evidence for an immune-mediated mechanism from a patient-specific in-vitro approach.
    Regen F, Herzog I, Hahn E, Ruehl C, Le Bret N, Dettling M, Heuser I, Hellmann-Regen J.
    Toxicol Appl Pharmacol; 2017 Feb 01; 316():10-16. PubMed ID: 27939987
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Clozapine-associated agranulocytosis: risk and aetiology.
    Krupp P, Barnes P.
    Br J Psychiatry Suppl; 1992 May 01; (17):38-40. PubMed ID: 1418887
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Clozapine and agranulocytosis: re-assessing the risks.
    Drew L.
    Australas Psychiatry; 2013 Aug 01; 21(4):335-7. PubMed ID: 23804114
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report.
    Barnas C, Zwierzina H, Hummer M, Sperner-Unterweger B, Stern A, Fleischhacker WW.
    J Clin Psychiatry; 1992 Jul 01; 53(7):245-7. PubMed ID: 1639744
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.